Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection

Volume 327:1779-1784		December 17, 1992		Number 25

Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection

PJ Ballem, A Belzberg, DV Devine, D Lyster, B Spruston, H Chambers, P Doubroff, and K Mikulash

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Abstract

BACKGROUND. Isolated thrombocytopenia accompanied by increased amounts of platelet-associated antibody is a common manifestation of human immunodeficiency virus (HIV) infection, and the thrombocytopenia often improves with zidovudine. It is not clear whether the mechanism of HIV-related thrombocytopenia primarily involves autoimmune destruction of platelets or reduced platelet production by megakaryocytes. METHODS. We studied the survival of 111In-labeled autologous platelets and performed platelet imaging in 24 men with isolated HIV-related thrombocytopenia (16 who received no treatment and 8 who received zidovudine). We also studied 20 HIV-infected men with normal platelet counts (10 who received no treatment and 10 who received zidovudine) and studied 12 healthy seronegative men as controls. RESULTS. Mean (+/- SD) platelet survival was significantly decreased in both the untreated and the zidovudine-treated patients with HIV-related thrombocytopenia (to 92 +/- 33 and 129 +/- 44 hours, respectively; both P < 0.001), as compared with the normal controls (198 +/- 15 hours). Mean platelet survival was also significantly decreased in the HIV-infected patients with normal platelet counts (untreated, 162 +/- 23 hours, P < 0.01; zidovudine-treated, 166 +/- 35 hours, P < 0.05). Imaging studies, however, revealed no evidence of increased clearance of autologous platelets in the liver or spleen in any of these groups. Mean platelet production was significantly depressed in the untreated patients with thrombocytopenia (23,000 +/- 11,000 platelets per cubic millimeter per day, P < 0.001) as compared with the healthy controls (45,000 +/- 6,000 per cubic millimeter per day). Mean platelet production was significantly increased, however, in the men treated with zidovudine, both in those with thrombocytopenia (60,000 +/- 31,000 platelets per cubic millimeter per day, P < 0.01 vs. controls) and in those without thrombocytopenia (68,000 +/- 22,000 per cubic millimeter per day, P < 0.01). CONCLUSIONS. Although there was a moderate reduction in platelet survival in HIV-infected persons, these patients, regardless of platelet counts, also had decreased production of platelets, possibly due to viral infection of the megakaryocytes. Zidovudine appears to improve platelet production.

Source Information

Department of Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.

This article has been cited by other articles:

Cines, D. B., Bussel, J. B., Liebman, H. A., Luning Prak, E. T. (2009). The ITP syndrome: pathogenic and clinical diversity. Blood 113: 6511-6521 [Abstract] [Full Text]
Baenziger, S., Heikenwalder, M., Johansen, P., Schlaepfer, E., Hofer, U., Miller, R. C., Diemand, S., Honda, K., Kundig, T. M., Aguzzi, A., Speck, R. F. (2009). Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 113: 377-388 [Abstract] [Full Text]
Liebman, H. A. (2008). Viral-Associated Immune Thrombocytopenic Purpura. ASH Education Book 2008: 212-218 [Abstract] [Full Text]
Thachil, J., Hall, G. W (2008). Is this immune thrombocytopenic purpura?. Arch. Dis. Child. 93: 76-81 [Full Text]
Wachtman, L. M., Skolasky, R. L., Tarwater, P. M., Esposito, D., Schifitto, G., Marder, K., McDermott, M. P., Cohen, B. A., Nath, A., Sacktor, N., Epstein, L. G., Mankowski, J. L., McArthur, J. C. (2007). Platelet Decline: An Avenue for Investigation Into the Pathogenesis of Human Immunodeficiency Virus Associated Dementia. Arch Neurol 64: 1264-1272 [Abstract] [Full Text]
Buffet, P. A., Milon, G., Brousse, V., Correas, J.-M., Dousset, B., Couvelard, A., Kianmanesh, R., Farges, O., Sauvanet, A., Paye, F., Ungeheuer, M.-N., Ottone, C., Khun, H., Fiette, L., Guigon, G., Huerre, M., Mercereau-Puijalon, O., David, P. H. (2006). Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood 107: 3745-3752 [Abstract] [Full Text]
Wong, R. S M, Wu, A., To, K F, Lee, N., Lam, C. W K, Wong, C K, Chan, P. K S, Ng, M. H L, Yu, L M, Hui, D. S, Tam, J. S, Cheng, G., Sung, J. J Y (2003). Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 326: 1358-1362 [Abstract] [Full Text]
Kuter, D. J., Begley, C. G. (2002). Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100: 3457-3469 [Abstract] [Full Text]
Arranz Caso, J. A., Sanchez Mingo, C., Garcia Tena, J. (1999). Effect of Highly Active Antiretroviral Therapy on Thrombocytopenia in Patients with HIV Infection. NEJM 341: 1239-1240 [Full Text]
Voulgaropoulou, F., Tan, B., Soares, M., Hahn, B., Ratner, L. (1999). Distinct Human Immunodeficiency Virus Strains in the Bone Marrow Are Associated with the Development of Thrombocytopenia. J. Virol. 73: 3497-3504 [Abstract] [Full Text]
Harker, L. A., Marzec, U. M., Novembre, F., Sundell, I. B., Waller, E. K., Karpatkin, S., McClure, H. M., Kelly, A. B., Stead, R. B. (1998). Treatment of Thrombocytopenia in Chimpanzees Infected With Human Immunodeficiency Virus by Pegylated Recombinant Human Megakaryocyte Growth and Development Factor. Blood 91: 4427-4433 [Abstract] [Full Text]
Cole, J. L., Marzec, U. M., Gunthel, C. J., Karpatkin, S., Worford, L., Sundell, I. B., Lennox, J. L., Nichol, J. L., Harker, L. A. (1998). Ineffective Platelet Production in Thrombocytopenic Human Immunodeficiency Virus-Infected Patients. Blood 91: 3239-3246 [Abstract] [Full Text]
Chelucci, C., Federico, M., Guerriero, R., Mattia, G., Casella, I., Pelosi, E., Testa, U., Mariani, G., Hassan, H.J., Peschle, C. (1998). Productive Human Immunodeficiency Virus-1 Infection of Purified Megakaryocytic Progenitors/Precursors and Maturing Megakaryocytes. Blood 91: 1225-1234 [Abstract] [Full Text]
Lord, R. V. N., Coleman, M. J., Milliken, S. T. (1998). Splenectomy for HIV-Related Immune Thrombocytopenia: Comparison With Results of Splenectomy for Non-HIV Immune Thrombocytopenic Purpura. Arch Surg 133: 205-210 [Abstract] [Full Text]
Tornquist, S. J., Crawford, T. B. (1997). Suppression of Megakaryocyte Colony Growth by Plasma From Foals Infected With Equine Infectious Anemia Virus. Blood 90: 2357-2363 [Abstract] [Full Text]
Nardi, M. A., Liu, L.-X., Karpatkin, S. (1997). GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic�thrombocytopenia. Proc. Natl. Acad. Sci. USA 94: 7589-7594 [Abstract] [Full Text]
Scaradavou, A., Woo, B., Woloski, B.M.R., Cunningham-Rundles, S., Ettinger, L. J., Aledort, L. M., Bussel, J. B. (1997). Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272�Patients. Blood 89: 2689-2700 [Abstract] [Full Text]
Forseter, G., Joline, C., Wormser, G. P. (1994). Tolerability, Safety, and Acceptability of Zidovudine Prophylaxis in Health Care Workers. Arch Intern Med 154: 2745-2749 [Abstract]
Landonio, G., Nosari, A., Spinelli, F., Pechere, M., Samii, K., Hirschel, B., Ballem, P., Belzberg, A., Devine, D. (1993). HIV-Related Thrombocytopenia. NEJM 328: 1785-1786 [Full Text]

Comments and questions? Please contact us.